# Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
Canonical URL: https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-to-participate-in-oppenheimer-36th-annual-healthcare-life-sciences-conference
Ticker: CMMB
Company: Chemomab Therapeutics
Source: Chemomab Therapeutics
Published: 2026-02-17 13:00 EST
Original Source URL: https://investors.chemomab.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-08 11:30 EST — [Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis](https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-and-precision-medicine-pioneer-scipher-medicine-announce-m-14c02ebe) — Source: Chemomab Therapeutics
- 2026-05-14 12:00 EST — [Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-announces-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Chemomab Therapeutics
- 2026-03-19 12:00 EST — [Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update](https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-announces-year-end-and-fourth-quarter-2025-financial-results-and-provides-a-corporate-update) — Source: Chemomab Therapeutics
- 2026-02-17 13:00 EST — [Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference](https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-to-participate-in-oppenheimer-36th-annual-healthcare-life-sciences-conference) — Source: Chemomab Therapeutics
- 2025-12-02 13:00 EST — [Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology](https://biopharmsignal.com/news/CMMB/chemomab-therapeutics-announces-nebokitug-phase-2-spring-trial-results-in-primary-sclerosing-cholangitis-published-in-the-american-journal-of-gastroenterology) — Source: Chemomab Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)